RxSight (RXST) Investor update summary

Strategic Collaboration and Product Pipeline

• Announced a collaboration with Alcon to develop adjustable presbyopia-correcting IOLs, leveraging both companies' expertise for noninvasive postoperative vision refinement.

• Proprietary hybrid IOL materials and next-generation light-adjustable technology are being developed for expanded patient customization and reduced postoperative treatments.

• Product pipeline includes next-generation LAL, LAL+, and LAL Toric, aiming for improved workflow, fewer required postoperative treatments, and best-in-class visual quality.

• Collaboration with Alcon validates the technology platform and IP, opening new innovation paths in the PC IOL space.

• The partnership is expected to deliver both near-term and long-term financial and strategic benefits.

Financial Performance and Guidance Update

• Preliminary Q2 2026 revenue expected at $32M–$34M, including $5M–$7M from the Alcon agreement; core sales down 20% year-over-year to ~$27M.

• 24,917 LAL units and 11 LDDs sold in Q2; installed base of LDDs grew to 1,166 units.

• Full-year 2026 revenue guidance revised to $140M–$160M, with $110M–$120M from core sales and $30M–$40M from the Alcon collaboration.

• Gross margin guidance raised to 73%–75% for 2026, above prior guidance of 70%–72%, reflecting favorable product mix.

• Operating expenses expected at the high end of $150M–$160M; quarter-end cash and equivalents at $209M as of June 30, 2026.

Market Dynamics and Commercial Strategy

• Q2 headwinds attributed to increased competitive trialing from new product launches and pressured consumer sentiment, leading to softer procedure activity.

• Competitive environment expected to remain active through year-end; guidance reflects ongoing headwinds.

• Commercial strategy includes accelerating customer re-engagement, expanding the U.S. LAL sales force, and investing in commercial capabilities.

• Early targeted commercial programs have shown success, supporting confidence in future growth.

• LDD pipeline impacted by competitive trialing, but rental models and OUS opportunities are being explored.